{"search_session":{},"preferences":{"l":"fr","queryLanguage":"fr"},"patentId":"052-310-731-969-326","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"052-310-731-969-326"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8903,"type":"PATENT","title":"Johns Hopkins Univ Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":17938,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8218,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and owners= \"Johns Hopkins Univ\", \"Univ Johns Hopkins\"
Select more for logical variants
Add to collection
Total patents: 12941
Search Applicants and Owners separately: Newcastle Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1333
Search applicants and owners= \"Johns Hopkins Univ\", \"Univ Johns Hopkins\"
Select more for logical variants
Add to collection
Total patents: 12941
Search Applicants and Owners separately: Newcastle Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1333
administering to the subject a polypeptide encoded by a polynucleotide that hybridizes under conditions comprising hybridization at 65° C. in 0.1×SSC to the complement of the portion of SEQ ID NO:3 that encodes from amino acid 26 to amino acid 341 of SEQ ID NO:4, wherein said polypeptide is administered in an amount sufficient to reduce airway hyper responsiveness or reduce the increase of mucus-containing cells in the airway epithelium."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said polypeptide comprises from amino acid 26 to amino acid 341 of SEQ ID NO:4."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein said polypeptide is part of fusion protein."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 3, wherein said fusion protein comprises an antibody fragment."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said polypeptide is part of a fusion protein."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein said fusion protein comprises an antibody fragment."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein said antibody fragment includes an Fc fragment."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the allergen-induced increase in airway hyper responsiveness is reduced."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the allergen-induced increase in mucus-containing cells in the airway epithelium is reduced."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["A method of administering a polypeptide to a mammalian subject having allergen-induced airway hyper responsiveness, or allergen-induced increase of mucus-containing cells in an airway epithelium, said method comprising administering a polypeptide encoded by a polynucleotide that hybridizes under conditions comprising hybridization at 65° C. in 0.1×SSC to the complement of the portion of SEQ ID NO:3 that encodes from amino acid 26 to amino acid 341 of SEQ ID NO:4 in an amount sufficient to decrease airway hyper responsiveness or reduce the increase of mucus-containing cells in the airway epithelium, wherein said polypeptide is administered by oral ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein said polypeptide comprises from amino acid 26 to amino acid 341 of SEQ ID NO:4."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 11, wherein said polypeptide is part of a fusion protein."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein said polypeptide is part of a fusion protein."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein said fusion protein comprises an antibody fragment."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein the subject has increased allergen-induced airway hyper responsiveness."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein the subject has an increase in allergen-induced mucus-containing cells in the airway epithelium."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating an inflammatory condition of the lung characterized by an increase in allergen-induced airway hyper responsiveness and mucus-containing cells in a mammalian subject said method comprising administering to the subject a therapeutically effective amount of a polypeptide encoded by a polynucleotide that hybridizes under conditions comprising hybridization at 65° C. in 0.1×SSC to complement of the portion of SEQ ID NO:3 that encodes from amino acid 26 to amino acid 341 of SEQ ID NO:4 in an amount sufficient to decrease the lung inflammation in the subject."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17, wherein said polypeptide comprises from amino acid 26 to amino acid 341 of SEQ ID NO:4."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 18, wherein said polypeptide is part of a fusion protein."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19, wherein said fusion comprises an antibody fragment."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 20, wherein said antibody fragment includes an Fc fragment."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of any of claim 1, 10 or 17, wherein the administration of the polypeptide results in complete reversal of the allergen-induced airway hyper responsiveness."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of any of claim 1, 10 or 17, wherein the administration of the polypeptide results in complete reversal of the allergen-induced increase in mucus-containing cells in the airway epithelium."],"number":23,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}